Immunotherapy, Thursday 1 March 2018


Organiser's Welcome Remarks

Alfred Scheidegger

Chair's Opening Remarks

Alfred Scheidegger, Chief Executive Officer, Nextech Invest

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Speed Networking


Exhibition Visit & Networking Refreshments

Advanced Therapy Landscape Overview: Where does Asia fit?


Chair's Opening Remarks

Frank Jiang

Cancer precision medicine: From screening to drug selection and development

  • Personalised, affordable and high efficacy are the ideal criteria of a medicine. But the big question is how do we actually move towards providing highly personalised medicine to patients in need?
  • Investigate the pathway to the future of medicine, from drug discovery, development to reaching out to the patients.
Han Chong Toh

Awakening the immune system against cancer - Moving into the clinic

Is cancer immunotherapy the beginning of the end of cancer? Discover cases where immunotherapy can be used to treat complicated cancer cases, including leukaemia, breast cancer and more.
Rajiv Rana

Global pipeline development to serve Asia population

  •     APAC strategy to develop promising pipeline for Asia-prevalent indications 
  •     Key pipelines sharing and thoughts on potential development collaboration in the region
  •     Shifting from cure to predictive and preventive studies: How are we doing so far?
  •     Moving beyond science & R&D: What are we lacking to advance towards creating personalised medicine in Asia

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 
Marc Voigt

The next big immune checkpoint: LAG-3

  •     The potential of LAG-3 in immune oncology and autoimmune diseases
  •     Combination therapy as a key therapeutic strategy in oncology
  •     Collaborations as a path to success in global drug development

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Avoiding delays to the clinic

John Moore, Director of Global Clinical Business Development, Vetter Pharma International

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: Why don’t we have an ICI in breast cancer – yet?

Stefan Gluck, Vice President of Global Medical Affairs, Celgene

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: Preparation steps to brace healthcare & pharma digital transformation

round tables

Table 9: Reconciling the diversified pharma regulations in Asia


Exhibition Visit & Networking Lunch


Frank Jiang

Chair's Opening Remarks

Victor Li

Anti-viral immunotherapy: A case study

Chronic viral infection predisposes a person to the development of cancer. The integrated viral genes in infected cells can be expressed to create viral peptides and presented onto the cell surface. Using our proprietary TCR platform, patient’s T cells can be engineered with high-avidity antiviral TCRs which recognize the tumor-specific viral peptides, leading to the release of cytolytic molecules and the lysis of cancer cells.
Bandana Sharan

Dendritic cell vaccines in Asia: The first CDSCO approved Indian dendritic cell cancer immunotherapy

Details to be announced
Himanshu Brahmbhatt

Nanocell platform for the targeted cyto-immunotherapy in cancer


Exhibition Visit & Networking Refreshments

Combination Immunotherapy

Stefan Gluck

Building the framework of combination immuno-oncology (I-O) (Topic to be finalised)

To be finalised
Stefan Gluck, Vice President of Global Medical Affairs, Celgene
Skye Hung-Chun Cheng

Using genetic information to predict the effectiveness of combination immunotherapy

  • Using molecular analytics in creating effective combinations
  • Disease modelling and prediction with big data and analytics
  • Case study sharing
Jin San Yoo

Expansions of trials and combination of Tanibirumab + anti-PD1 antibody for refractory cancer patients

    style="font-size: 10.0pt;">
  •     Insights learnt from Tanibirumab recurrent GBM phase IIa open labelled three arms multi-centre trial in Australia
  •     Expansions of trails for combination of Tanibirumab + anti-PD1 antibody for refractory tumours 

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 19/Jan/18 08:15

Immunotherapy, Friday 2 March 2018


Organiser's Welcome Remarks


Chair's Opening Remarks

Disruption & Digitalisation

Tony Liu

Shifting paradigm of the advanced therapy landscape in Asia

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. From a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Upon approval for commercial deployment, what else needs to be done to help patients afford the sky high cost of immunotherapy? Join this thought provoking presentation to hear from Tony Liu, CEO of CBMG and former senior executive of Alibaba and Microsoft to learn how this influential biopharma company take steps to prepare for the next miracle drug in making. 
Antonio Lee

Innovation beyond limit: How do we conquer incurable diseases and create new history

Advancement in research helps to push the limitation of treatment paradigm to attempt curing currently incurable diseases. Innovative therapeutic solutions however is often not sufficient without a strong team to help with commercialisation. In this presentation, Antonio will share about the overall landscape in Asia stem cell therapy, challenges in current landscape and opportunities ahead to achieve commercial excellence.  
Ivor Lim

Educated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.

Exhibition Visit & Networking Refreshments


Exhibition Visit & Networking Lunch


Chair's Opening Remarks

Alfred Scheidegger

Global Immuno-Oncology Investment Trends & Opportunities

Alfred Scheidegger, Chief Executive Officer, Nextech Invest

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
Sebastian Sujka

AI in pharma: Using digital technology for disease prevention

Sebastian Sujka, CEO & Co-Founder, Xbird, Bayer’s Grants4Apps

Exhibition Visit & Networking Refreshments

Close of Phar-East 2018

last published: 19/Jan/18 08:15